On Monday, Heron Therapeutics Inc (NASDAQ: HRTX) opened higher 1.37% from the last session, before settling in for the closing price of $2.91. Price fluctuations for HRTX have ranged from $0.50 to $3.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 17.85% over the last five years. Company’s average yearly earnings per share was noted 73.39% at the time writing. With a float of $142.67 million, this company’s outstanding shares have now reached $150.29 million.
The firm has a total of 126 workers. Let’s measure their productivity.
Heron Therapeutics Inc (HRTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Heron Therapeutics Inc is 5.10%, while institutional ownership is 71.14%. The most recent insider transaction that took place on Nov 17 ’23, was worth 27,250. In this transaction EVP, Chief Development Officer of this company bought 25,000 shares at a rate of $1.09, taking the stock ownership to the 79,000 shares. Before that another transaction happened on Nov 16 ’23, when Company’s Chief Executive Officer bought 150,000 for $0.92, making the entire transaction worth $137,970. This insider now owns 186,496 shares in total.
Heron Therapeutics Inc (HRTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 397.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.50% during the next five years compared to 20.01% growth over the previous five years of trading.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
Check out the current performance indicators for Heron Therapeutics Inc (HRTX). In the past quarter, the stock posted a quick ratio of 1.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Analysing the last 5-days average volume posted by the [Heron Therapeutics Inc, HRTX], we can find that recorded value of 1.71 million was lower than the volume posted last year of 2.82 million. As of the previous 9 days, the stock’s Stochastic %D was 83.40%. Additionally, its Average True Range was 0.20.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 87.20%, which indicates a significant increase from 77.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.70% in the past 14 days, which was lower than the 93.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.70, while its 200-day Moving Average is $1.72. Now, the first resistance to watch is $3.06. This is followed by the second major resistance level at $3.18. The third major resistance level sits at $3.28. If the price goes on to break the first support level at $2.85, it is likely to go to the next support level at $2.75. Now, if the price goes above the second support level, the third support stands at $2.63.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
There are currently 150,329K shares outstanding in the company with a market cap of 443.47 million. Presently, the company’s annual sales total 127,040 K according to its annual income of -110,560 K. Last quarter, the company’s sales amounted to 34,230 K and its income totaled -10,720 K.
